{"id":"placebo-by-intravenously-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Nocebo effects (adverse events attributed to placebo expectation)"},{"rate":null,"effect":"Injection site reactions (from IV administration)"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo by intravenously administration","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:52:17.419943+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:52:23.606105+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo by intravenously administration","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:52:23.975184+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5783405/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:52:24.700722+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo administered intravenously acts through expectation, conditioning, and the patient's belief in treatment rather than through direct molecular interaction. The intravenous route may enhance the placebo effect by increasing perceived treatment intensity. This is typically used in clinical research settings to serve as a control comparator for evaluating the true efficacy of active pharmaceutical agents.","oneSentence":"Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:40.802Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:52:26.436042+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Clinical research control / comparator in randomized controlled trials"}]},"trialDetails":[{"nctId":"NCT06964776","phase":"PHASE1","title":"A Study of LY4268989 (MORF-057) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2025-05-01","conditions":"Healthy","enrollment":144},{"nctId":"NCT03540368","phase":"NA","title":"Tranexamic Acid for The Treatment of Gastrointestinal Bleeding","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2018-07-01","conditions":"Gastrointestinal Bleeding","enrollment":48},{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT06119581","phase":"PHASE3","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-12-21","conditions":"Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis","enrollment":1264},{"nctId":"NCT06890598","phase":"PHASE3","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":700},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT04543591","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-10","conditions":"Thrombotic Microangiopathy","enrollment":148},{"nctId":"NCT07207811","phase":"PHASE3","title":"CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-10-02","conditions":"Transthyretin Amyloid Cardiomyopathy (ATTR CM)","enrollment":1280},{"nctId":"NCT07462819","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of Intravenous Stemis™ in Elderly Subjects With Mild to Moderate Frailty Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Ji Yan Biomedical Co., Ltd.","startDate":"2026-04","conditions":"Frailty Syndrome","enrollment":12},{"nctId":"NCT04639050","phase":"PHASE1, PHASE2","title":"Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-15","conditions":"Alzheimers Disease","enrollment":241},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT04033445","phase":"PHASE2, PHASE3","title":"A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-26","conditions":"Ulcerative Colitis","enrollment":1064},{"nctId":"NCT06265051","phase":"PHASE2, PHASE3","title":"Tirofiban After Successful MT Recanalization in AIS","status":"COMPLETED","sponsor":"Xiang Luo","startDate":"2024-04-09","conditions":"Acute Ischemic Stroke, Vessel Occlusion","enrollment":1380},{"nctId":"NCT07456670","phase":"PHASE2","title":"Caffeine for Infants Born at 28 to 34 Weeks Receiving Respiratory Support","status":"NOT_YET_RECRUITING","sponsor":"Queen's University","startDate":"2026-04-01","conditions":"Preterm Birth, Caffeine, Neonatal Outcomes","enrollment":62},{"nctId":"NCT07440069","phase":"PHASE4","title":"Analgesic Efficacy and Obstetric Effects of Tramadol, Paracetamol and Placebo in Active Labor","status":"RECRUITING","sponsor":"Universidad Nacional Autonoma de Honduras","startDate":"2026-02-15","conditions":"Labor Pain","enrollment":300},{"nctId":"NCT07441226","phase":"PHASE2","title":"Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients","status":"RECRUITING","sponsor":"RSUP Persahabatan","startDate":"2025-08-08","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":20},{"nctId":"NCT07423000","phase":"PHASE1","title":"A Phase 1 Study of PVT401 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Parvus Therapeutics, Inc.","startDate":"2026-04","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":36},{"nctId":"NCT04221945","phase":"PHASE3","title":"Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-12","conditions":"Uterine Cervical Neoplasms","enrollment":1060},{"nctId":"NCT07415655","phase":"PHASE2","title":"Modulation of Cerebral Ischemia by Albumin","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Hradec Kralove","startDate":"2026-02-03","conditions":"Ischemic Stroke","enrollment":100},{"nctId":"NCT01760005","phase":"PHASE2, PHASE3","title":"Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2012-12","conditions":"Alzheimers Disease, Dementia, Alzheimers Disease, Familial","enrollment":490},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT05269394","phase":"PHASE2, PHASE3","title":"Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-12-22","conditions":"Alzheimers Disease, Dementia, Alzheimers Disease, Familial","enrollment":197},{"nctId":"NCT07250750","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis","status":"RECRUITING","sponsor":"ImmunAbs Inc.","startDate":"2026-02-05","conditions":"Myasthenia Gravis","enrollment":96},{"nctId":"NCT05929677","phase":"EARLY_PHASE1","title":"Impulsivity Domains and Subjective Response","status":"RECRUITING","sponsor":"Jessica Weafer","startDate":"2024-04-01","conditions":"Alcohol Use Disorder","enrollment":250},{"nctId":"NCT04040452","phase":"PHASE4","title":"Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery","status":"RECRUITING","sponsor":"Phoenix Children's Hospital","startDate":"2021-03-01","conditions":"Congenital Heart Disease in Children","enrollment":166},{"nctId":"NCT07353749","phase":"PHASE4","title":"Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms","status":"NOT_YET_RECRUITING","sponsor":"Duan Chuanzhi","startDate":"2026-01-30","conditions":"Unruptured Intracranial Aneurysms, Cerebrovascular Event, Hemorrhagic Stroke","enrollment":864},{"nctId":"NCT06143059","phase":"PHASE3","title":"The Effects of Sex Hormones and Alcohol on Sleep","status":"SUSPENDED","sponsor":"Lauren Whitehurst","startDate":"2024-01-08","conditions":"Alcohol Use Disorder","enrollment":130},{"nctId":"NCT03470441","phase":"PHASE2","title":"A Study of Acute Myocardial Infarction Using FDY-5301","status":"COMPLETED","sponsor":"Faraday Pharmaceuticals, Inc.","startDate":"2017-10-27","conditions":"Acute Myocardial Infarction, STEMI","enrollment":120},{"nctId":"NCT05394116","phase":"PHASE3","title":"A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-11-21","conditions":"Fibrodysplasia Ossificans Progressiva","enrollment":63},{"nctId":"NCT04921384","phase":"PHASE3","title":"Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2021-05-29","conditions":"Migraine","enrollment":981},{"nctId":"NCT05310968","phase":"PHASE4","title":"Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-11-12","conditions":"Branch Atheromatous Disease","enrollment":970},{"nctId":"NCT07336992","phase":"PHASE3","title":"Efficacy of Prophylactic Levetiracetam for Improving Functional Outcome in the Acute Phase of Intracerebral Haemorrhage: a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01-02","conditions":"Spontaneous Intracerebral Hemorrhage","enrollment":580},{"nctId":"NCT06493084","phase":"PHASE1","title":"Evaluate LAE102 in Healthy and Overweight/Obese Subjects","status":"RECRUITING","sponsor":"Laekna Limited","startDate":"2024-06-25","conditions":"Overweight and Obese Volunteers","enrollment":160},{"nctId":"NCT01492686","phase":"PHASE3","title":"Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":137},{"nctId":"NCT00424463","phase":"PHASE3","title":"Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":181},{"nctId":"NCT00330681","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-05","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":206},{"nctId":"NCT00415519","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":25},{"nctId":"NCT07277153","phase":"PHASE4","title":"Clinical Study on the Effect of Tegileridine on Postoperative Pain in Patients Undergoing Abdominal Surgery.","status":"COMPLETED","sponsor":"Xin Chen","startDate":"2025-10-18","conditions":"Laparoscopic Surgery for Cholecystitis","enrollment":150},{"nctId":"NCT04673357","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-06","conditions":"Crohn Disease","enrollment":101},{"nctId":"NCT07252752","phase":"NA","title":"Dopamine and Insulin in Psychosis","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2026-01-01","conditions":"First Episode Psychosis (FEP)","enrollment":46},{"nctId":"NCT06798454","phase":"PHASE1","title":"Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)","status":"COMPLETED","sponsor":"Parvus Therapeutics, Inc.","startDate":"2024-10-15","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":24},{"nctId":"NCT06047171","phase":"PHASE2","title":"Rescue of Nephrons With ALE.F02 (RENAL-F02)","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2023-09-07","conditions":"Glomerulonephritis Rapidly Progressive","enrollment":80},{"nctId":"NCT06441682","phase":"PHASE2","title":"A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-10-23","conditions":"Amyotrophic Lateral Sclerosis","enrollment":60},{"nctId":"NCT07239115","phase":"PHASE3","title":"Levetiracetam for Seizure Prevention After Brain Tumor Surgery","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-01","conditions":"Postoperative Seizures After Brain Tumor Surgery","enrollment":558},{"nctId":"NCT07232147","phase":"PHASE1","title":"Clinical Research on Stem Cell Therapy for Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","startDate":"2025-12-01","conditions":"Parkinson Disease (PD), Neurodegenerative Diseases, Movement Disorders","enrollment":20},{"nctId":"NCT06908707","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women","status":"COMPLETED","sponsor":"Laekna Limited","startDate":"2025-04-22","conditions":"Postmenopausal, Healthy Adult Female Participants","enrollment":32},{"nctId":"NCT06028438","phase":"PHASE2","title":"A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-15","conditions":"Arthritis, Rheumatoid","enrollment":103},{"nctId":"NCT06947928","phase":"PHASE2, PHASE3","title":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma","status":"RECRUITING","sponsor":"TuHURA Biosciences, Inc.","startDate":"2025-10","conditions":"Advanced Or Metastatic Merkel Cell Carcinoma","enrollment":118},{"nctId":"NCT05479981","phase":"PHASE2","title":"Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients","status":"COMPLETED","sponsor":"Avidity Biosciences, Inc.","startDate":"2022-08-04","conditions":"DM1, Muscular Dystrophies, Myotonic Dystrophy","enrollment":37},{"nctId":"NCT07144956","phase":"PHASE3","title":"Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2025-12-15","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":630},{"nctId":"NCT00532155","phase":"PHASE3","title":"A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Carcinoma, Non Small Cell Lung","enrollment":913},{"nctId":"NCT04113109","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-01","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT04154982","phase":"PHASE2","title":"N-Acetylcysteine Protection Against Radiation Induced Cellular Damage","status":"COMPLETED","sponsor":"Centro Cardiologico Monzino","startDate":"2020-09-02","conditions":"Cardiac Arrhythmia","enrollment":181},{"nctId":"NCT03322540","phase":"PHASE2","title":"Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-12-15","conditions":"Lung Cancer","enrollment":154},{"nctId":"NCT02993523","phase":"PHASE3","title":"A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2017-02-02","conditions":"Acute Myeloid Leukemia (AML)","enrollment":443},{"nctId":"NCT04543383","phase":"PHASE1","title":"A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-27","conditions":"Healthy","enrollment":52},{"nctId":"NCT02813655","phase":"PHASE2","title":"Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2016-10","conditions":"Post-dural Puncture Headache","enrollment":46},{"nctId":"NCT04839354","phase":"PHASE3","title":"Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial","status":"COMPLETED","sponsor":"Claudia R. Morris","startDate":"2021-06-21","conditions":"Sickle Cell Disease","enrollment":271},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT06886230","phase":"PHASE4","title":"Ondansetron vs. Dexamethasone for Postoperative Nausea","status":"COMPLETED","sponsor":"Hafiz Muhammad Hamza","startDate":"2025-03-20","conditions":"Postoperative Nausea and Vomiting (PONV)","enrollment":105},{"nctId":"NCT04406272","phase":"PHASE2","title":"VB-111 in Surgically Accessible Recurrent/Progressive GBM","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":15},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT04832009","phase":"EARLY_PHASE1","title":"Reversing Glucose and Lipid-mediated Vascular Dysfunction","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-05-09","conditions":"Blood Pressure, Hypertension","enrollment":46},{"nctId":"NCT02877134","phase":"PHASE2","title":"Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-25","conditions":"Crohn Disease","enrollment":388},{"nctId":"NCT05463731","phase":"PHASE3","title":"A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-08-01","conditions":"Alzheimer's Disease","enrollment":1667},{"nctId":"NCT04141696","phase":"PHASE1, PHASE2","title":"A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue","status":"COMPLETED","sponsor":"National Institute of Nursing Research (NINR)","startDate":"2021-07-26","conditions":"Fatigue","enrollment":10},{"nctId":"NCT04593784","phase":"PHASE2","title":"Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults","status":"TERMINATED","sponsor":"AMAG Pharmaceuticals, Inc.","startDate":"2021-10-13","conditions":"Healthy","enrollment":41},{"nctId":"NCT02187003","phase":"PHASE3","title":"Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease","status":"COMPLETED","sponsor":"Biossil Inc.","startDate":"2015-06-17","conditions":"Anemia, Sickle Cell","enrollment":345},{"nctId":"NCT02766322","phase":"","title":"Alcohol and Bariatric Surgery","status":"TERMINATED","sponsor":"University of Illinois at Urbana-Champaign","startDate":"2016-03","conditions":"Obesity","enrollment":54},{"nctId":"NCT06251609","phase":"PHASE2","title":"Naloxone for Opioid Associated Out of Hospital Cardiac Arrest","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-11","conditions":"Heart Arrest, Out-Of-Hospital, Opioid Overdose, Naloxone","enrollment":98},{"nctId":"NCT04825288","phase":"PHASE1, PHASE2","title":"XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"XBiotech, Inc.","startDate":"2021-05-27","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT02163694","phase":"PHASE3","title":"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04-08","conditions":"Metastatic Breast Cancer","enrollment":513},{"nctId":"NCT06749756","phase":"NA","title":"Study on the Improvement of Microcirculation in Patients With Sepsis by Vitamin B6, Vitamin B12 and Vitamin C","status":"RECRUITING","sponsor":"Fan Zeng","startDate":"2025-02-10","conditions":"Septic Shock","enrollment":296},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT03628924","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-04","conditions":"Hidradenitis Suppurativa","enrollment":184},{"nctId":"NCT06623370","phase":"PHASE4","title":"The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group","status":"COMPLETED","sponsor":"Konya City Hospital","startDate":"2024-10-01","conditions":"Sugammadex Reversal Time, Muscle Weakness","enrollment":80},{"nctId":"NCT05895838","phase":"PHASE3","title":"The Danish Out-of-Hospital Cardiac Arrest Study","status":"RECRUITING","sponsor":"Christian Hassager","startDate":"2023-06-16","conditions":"Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome","enrollment":1000},{"nctId":"NCT06740149","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03-01","conditions":"Acute-On-Chronic Liver Failure","enrollment":90},{"nctId":"NCT05441410","phase":"PHASE1, PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":"Malaria","enrollment":30},{"nctId":"NCT06717490","phase":"NA","title":"Magnesium Sulfate and Postoperative Hypercoagulability in Laparoscopic Gynecological Surgeries","status":"RECRUITING","sponsor":"Marianna Mavromati","startDate":"2024-12","conditions":"Magnesium Sulfate, Thromboelastometry","enrollment":60},{"nctId":"NCT06538558","phase":"PHASE1","title":"Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder","status":"RECRUITING","sponsor":"Proniras Corporation","startDate":"2024-10-16","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT04742660","phase":"NA","title":"The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Konkuk University Medical Center","startDate":"2021-05-11","conditions":"Postoperative Nausea","enrollment":224},{"nctId":"NCT04912518","phase":"NA","title":"Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction","status":"RECRUITING","sponsor":"Harbin Medical University","startDate":"2021-05-27","conditions":"ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection","enrollment":250},{"nctId":"NCT03355053","phase":"PHASE2","title":"Investigation of Sleep in the Intensive Care Unit","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-05-29","conditions":"Delirium, Sleep","enrollment":522},{"nctId":"NCT01143064","phase":"PHASE3","title":"Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury","status":"COMPLETED","sponsor":"BHR Pharma, LLC","startDate":"2010-06","conditions":"Brain Injuries","enrollment":1195},{"nctId":"NCT06622564","phase":"PHASE3","title":"Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-01-01","conditions":"Bleeding, Surgical Blood Loss, Seizures","enrollment":40},{"nctId":"NCT04743804","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-06-29","conditions":"Thrombotic Microangiopathy","enrollment":16},{"nctId":"NCT02578680","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-15","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":616},{"nctId":"NCT04688775","phase":"PHASE3","title":"Eptinezumab in Participants With Episodic Cluster Headache","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2020-12-23","conditions":"Cluster Headache, Episodic","enrollment":231},{"nctId":"NCT03989336","phase":"PHASE2","title":"A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2020-12-23","conditions":"Ovarian Cancer","enrollment":84},{"nctId":"NCT03037931","phase":"PHASE3","title":"Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2017-03-15","conditions":"Heart Failure, Iron-deficiency","enrollment":3065},{"nctId":"NCT04313881","phase":"PHASE3","title":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2020-09-09","conditions":"Myelodysplastic Syndromes","enrollment":539},{"nctId":"NCT03950674","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-02-22","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":40},{"nctId":"NCT03817125","phase":"PHASE1","title":"Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention","status":"COMPLETED","sponsor":"Parker Institute for Cancer Immunotherapy","startDate":"2019-01-28","conditions":"Metastatic Melanoma","enrollment":14},{"nctId":"NCT04465539","phase":"NA","title":"The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning","status":"COMPLETED","sponsor":"Tanta University","startDate":"2020-07-15","conditions":"Potential Therapeutic Role","enrollment":60},{"nctId":"NCT06376630","phase":"NA","title":"Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI","status":"RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2024-01-29","conditions":"Myocardial Infarction, Coronary Stenosis, Coronary Microvascular Dysfunction","enrollment":300},{"nctId":"NCT06333821","phase":"PHASE3","title":"A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2024-04-01","conditions":"Cervical Cancer","enrollment":460},{"nctId":"NCT04899921","phase":"PHASE2","title":"Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-30","conditions":"Melanoma, Metastatic Melanoma","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL5783405"},"_approvalHistory":[],"publicationCount":6490,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Saline by intravenously administration"],"phase":"marketed","status":"active","brandName":"Placebo by intravenously administration","genericName":"Placebo by intravenously administration","companyName":"Shenzhen Kangning Hospital","companyId":"shenzhen-kangning-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes. Used for Clinical research control / comparator in randomized controlled trials.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:52:26.436042+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}